Inflammation and Colchicine use in patients with ESRF undergoing Dialysis
Understanding the Inflammatory mechanisms and effect of Colchicine in patients with End stage renal failure undergoing Dialysis
A/Prof Sanjay Patel
100 participants
Aug 1, 2017
Interventional
Conditions
Summary
This study aims to look at the inflammatory processes in patients with kidney disease who require haemodialysis. It has been shown that there is a pro-inflammatory process in this cohort of patients and this study intends to look at the specific mechanisms, immune cellular function and inflammatory molecules involved in this process. It also intends to look at the effect of Colchicine, an anti-inflammatory agent on the level of inflammatory molecules
Eligibility
Inclusion Criteria1
- Patients with end stage renal failure on haemodialysis
Exclusion Criteria7
- Known hypersensitivity to colchicine
- Moderate hepatic dysfunction (Alanine Aminotransferase 1.5x upper limit of normal range)
- Thrombocytopaenia or leukopaenia
- Pregnant or lactating women and women at risk of pregnancy
- Patients taking moderate-strong CYP3A4 inhibitors
- Patients already taking Colchicine
- Those with evidence of active infection of inflammatory conditions that might be associated with markedly elevated CRP levels in the blood and those taking other anti-inflammatory therapies
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral Administration of 1mg Colchicine as an initial dose followed by another 0.5mg second dose one hour later. Tablet administration will be performed by healthcare personnel to confirm adherence
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617000922370